Published Date: 13 Mar 2023
The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.
Read Full News1.
TULSA Is Effective in Long-Term Prostate Cancer Control.
2.
For fit patients with CLL, frontline venetoclax-ibrutinib improves survival.
3.
Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib
4.
Childhood brain tumors develop early in highly specialized nerve cells, research reveals
5.
Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer
1.
Beyond the Blood: Expanding CAR T-Cell Therapy to Solid Tumors- A New Era of Precision Oncology
2.
Transformative Approaches in Hematology for Healthcare Excellence
3.
General Practitioners Role in Diagnosing Ovarian Cancer
4.
Unlocking the Potential of Talquetamab: A Revolutionary Approach to Cancer Treatment
5.
Exercise Capacity During Cancer Recovery: Clinical Evidence, Mechanisms, and Practical Implications
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
1.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
3.
Clinical Insights in Hematology
4.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation